# Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

> **NCT00150592** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 182 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** SPD503 (Guanfacine HCl)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00150592
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05-12
- **Primary completion:** 2005-10-05
- **Final completion:** 2005-10-05
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150592, "Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00150592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*